Stage III Non-Small Cell Lung Cancer
Evaluation and Staging
Good Practice Point
- A complete resection (R0) of the primary tumor and involved lymph nodes is deemed possible.
- N3 lymph nodes are deemed to be not involved by multidisciplinary consensus.
- Perioperative (90-day) mortality is expected to be low (≤5%).
Good Practice Points
- CT: Computed Tomography
- EGFR: Epidermal Growth Factor Receptor
- FDG PET: Fluorodeoxyglucose-positron Emission Tomography
- Gy: Gray
- NSCLC: Non-small Cell Lung Cancer
- PD-L1: Programmed Death Ligand 1
Management of Stage III Non-Small Cell Lung Cancer
July 20, 2023
Supplemental Implementation Tools
Country of Publication
The purpose of this guideline is to provide evidence-based recommendations to practicing clinicians on management of patients with stage III non–small-cell lung cancer (NSCLC), and to help clinicians involved in the diagnosis and treatment of lung cancer accurately confirm the presence of stage III non–small-cell lung cancer (NSCLC) and offer the most appropriate treatments.
Target Patient Population
Patients with stage III NSCLC
Target Provider Population
Medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, radiologists, primary care physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other providers
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient, Radiology services
Nurse, nurse practitioner, physician, physician assistant, radiology technologist
Assessment and screening, Treatment, Management
D002289 - Carcinoma, Non-Small-Cell Lung, D017024 - Chemotherapy, Adjuvant, D020360 - Neoadjuvant Therapy, D059248 - Chemoradiotherapy, D059186 - Chemoradiotherapy, Adjuvant
lung cancer, non-small cell lung cancer, non-small-cell lung carcinoma (NSCLC), NSCLC, Stage III, stage IIIA
Singh N, Daly ME, Ismaila N, et al. Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023 Jul 20. doi:10.1200/JCO.23.01261
Daly ME, Singh N, Ismaila N, et al. Management of Stage III NSCLC: ASCO Guideline. J Clin Oncol. 2021 Dec 22. doi:10.1200/JCO.21.02528